It is therefore important to take into account that a combined therapeutic intervention with thoracic irradiation and an anti-CD73 mAB might not only synergize in anti-tumor immunity and limit chronic toxicities (fibrosis), but also synergize in subacute normal tissue toxicities such as radiation pneumonitis to exert stronger adverse effects, if not compensated by other mechanisms (De Leve et al., 2019b). The gene discussed is NT5E; the disease is radiation pneumonitis.